# AGEN1777 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/agen1777

> AGEN1777, sponsored by AGENUS INC (AGEN): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | AGEN1777 |
| Codes | AGEN1777 |
| Sponsor | AGENUS INC (AGEN) https://sec-api.dev/companies/agen/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2021: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0000950170-24-125608): "In October 2021, we achieved a $20.0 million milestone upon the dosing of the first patient in the AGEN1777 Phase 1 clinical trial and in December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a" https://www.sec.gov/Archives/edgar/data/1098972/000095017024125608/agen-20240930.htm

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-17, last confirmed 2026-03-16.
- SEC Form 10-K (accession 0001193125-26-108632): "In October 2021, we achieved a $20.0 million milestone upon the dosing of the first patient in the AGEN1777 Phase 1 clinical trial and in December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a $25.0 million milestone." https://www.sec.gov/Archives/edgar/data/1098972/000119312526108632/agen-20251231.htm
- SEC Form 10-Q (accession 0000950170-25-069396): "In October 2021, we achieved a $20.0 million milestone upon the dosing of the first patient in the AGEN1777 Phase 1 clinical trial and in December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a" https://www.sec.gov/Archives/edgar/data/1098972/000095017025069396/agen-20250331.htm
- SEC Form 10-K (accession 0000950170-25-040289): "In October 2021, we announced that the first patient was dosed in the AGEN1777 Phase 1 clinical trial, triggering the achievement of a $20.0 million milestone and in December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a $25.0 million milestone." https://www.sec.gov/Archives/edgar/data/1098972/000095017025040289/agen-20241231.htm
- SEC Form 10-K (accession 0000950170-25-040289): "In October 2021, we achieved a $20.0 million milestone upon the dosing of the first patient in the AGEN1777 Phase 1 clinical trial and in December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a $25.0 million milestone." https://www.sec.gov/Archives/edgar/data/1098972/000095017025040289/agen-20241231.htm
- SEC Form 10-K (accession 0001193125-26-108632): "In December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a $25.0 million milestone." https://www.sec.gov/Archives/edgar/data/1098972/000119312526108632/agen-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-274554): "December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a $25.0 million milestone." https://www.sec.gov/Archives/edgar/data/1098972/000119312525274554/agen-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-106633): "December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a $25.0 million milestone." https://www.sec.gov/Archives/edgar/data/1098972/000095017025106633/agen-20250630.htm
- SEC Form 10-K (accession 0000950170-25-040289): "In December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a $25.0 million milestone." https://www.sec.gov/Archives/edgar/data/1098972/000095017025040289/agen-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/agen1777.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AGEN1777 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/agen1777

```bibtex
@misc{secapidev_pdufa_agen1777_20261116,
  title        = {AGEN1777 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/agen1777}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_agen1777_20261116","title":"AGEN1777 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/agen1777","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
